NewsSource: EClinCloud Official Website Historical Archive

EClinCloud Invited to Join the AI+ Biopharmaceutical Ecosystem Alliance to Build an Intelligent Innovation Ecosystem Together

1 min readEClinCloud Editorial Team
EClinCloud Invited to Join the AI+ Biopharma Ecosystem Alliance to Jointly Build an Intelligent Innovation Ecosystem! Archived article cover

AI与生物医药生态圈联盟活动现场  

AI+ Biopharmaceutical Ecosystem Alliance Launch Ceremony

First from the right: EClinCloud Co-founder & Chief Business Officer Su Quanyu

 

On October 28, the Harbour BioMed Global R&D Day ("Illuminating Harbour with Intelligence, Gathering Stars of Innovation") was successfully held in Shanghai, China. At the event, the AI+ Biopharmaceutical Ecosystem Alliance was officially launched. EClinCloud was invited to attend as an alliance member; the company's Co-founder & Chief Business Officer Su Quanyu attended in person and joined industry peers to witness the inauguration of the alliance.

The AI+ Biopharma Ecosystem Alliance initiative has received support from multiple parties, including government bodies, industry associations, enterprises, and investment institutions.

Bringing together top expertise, technologies, and resources from across society—with members including innovative companies such as EClinCloud and investment institutions, among others—the alliance aims to systematically reshape the entire drug R&D process through artificial intelligence technologies and accelerate innovative therapies to benefit patients worldwide.

The AI+ Biopharma Ecosystem Alliance is committed to building an open, collaborative, and mutually beneficial ecosystem that will jointly address major challenges in drug R&D through a clear value-sharing mechanism. Going forward, the alliance will rely on collaborative innovation to improve the success rate of drug R&D and deliver breakthrough therapies to patients faster and more effectively.

EClinCloud is honored to join the AI+ Biopharma Ecosystem Alliance. AI is profoundly reshaping every stage of clinical R&D. As a technology company with AI as its core driving force, we will continue to work with industry partners to jointly explore the limitless possibilities of "AI-enabled clinical research" and provide smarter, more efficient digital solutions for new drug development.